[1] Gilhooley E, Daly S, McKenna D. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Dermatology. 2021;237(6):995-999.
[2] Boo YC. Up- or Downregulation of Melanin Synthesis Using Amino Acids, Peptides, and Their Analogs. Biomedicines. 2020 Sep 1;8(9):322.
[3] Ross St, C Barnetson, Terry K.T. Ooi, Liqing Zhuang, et al. [Nle4-D-Phe7]-α-Melanocyte-Stimulating Hormone Significantly Increased Pigmentation and Decreased UV Damage in Fair-Skinned Caucasian Volunteers, Journal of Investigative Dermatology, Volume 126, Issue 8, August 2006, Pages 1869-1878
[4] Eliason NL, Martin L, Low MJ, Sharpe AL. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022 Dec;96:102289
[5] Bassett PA, Abbara A, Goldmeier D, Comninos AN, Dhillo WS. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. J Clin Invest. 2022 Oct 3;132(19):e152341.
[6] Evans-Brown, Michael & Dawson, Rob & Chandler, Martin & Mcveigh, Jim. (2009). Use of melanotan I and II in the general population. BMJ. 338. 10.1136/bmj.b566.
[7] Royalty JE, Konradsen G, Eskerod O, Wulff BS, Hansen BS. Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects. J Clin Pharmacol. 2014 Apr;54(4):394-404.